We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Digital CTC Assay Improves Liver Cancer Diagnosis

By LabMedica International staff writers
Posted on 01 Feb 2017
Liver cancer, including hepatocellular carcinoma (HCC), is the second highest cause of cancer death in the world. More...
HCC is particularly prevalent in developing countries, where its incidence is driven by infection with the hepatitis B virus, which now affects more than 248 million individuals.

The use of an advanced form of the commonly used polymerase chain reaction (PCR) method to analyze circulating tumor cells may greatly increase the ability to diagnose early-stage cancer, increasing the likelihood of successful treatment as current blood-based strategies for detecting HCC, such as serum levels of alpha-fetoprotein (AFP), have had poor results.

A large team of scientists working with those at Massachusetts General Hospital Cancer Center developed a digital PCR assay by first identifying 10 specific ribonucleic acid (RNA) transcripts that were expressed in HCC cells but not in blood components. They assayed blood samples from six groups of individuals: newly diagnosed HCC patients; HCC patients receiving treatment who still had evidence of disease; HCC patients who appeared to be cured after surgical treatment, including liver transplantation; patients at risk for developing HCC because of other chronic liver diseases; patients with other types of cancer, including some with liver metastases; and healthy volunteers.

The circulating tumor cells (CTC)-iChip digital PCR analysis revealed significantly higher levels of the HCC-associated RNA transcripts in blood samples from patients with HCC than from those with other cancers, with chronic liver disease or healthy controls. The use of a CTC score based on the nine RNA transcripts most significantly associated with HCC generated positive results for more than half of those with untreated HCC, but only around 8% of healthy controls and 3% of those with other liver diseases. Around 28% of patients currently being treated had positive scores, and the percentage of positive scores among patients with no evidence of disease after treatment was similar to that of healthy controls.

Mark Kalinich, an MD/PhD candidate and co-lead author of the study said, “We have developed an assay capable of detecting a single cancer cell within a background of the tens of billions of cells that comprise whole blood. Our test provides highly specific detection of cancer in patients with HCC, compared with healthy individuals and with those at high risk for developing the disease. These results hold promise for both the early detection of HCC and for the monitoring of treatment over time.” The study was published on January 17, 2017, in the Proceedings of the National Academy of Sciences of the United States of America.


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.